Hidradenitis Suppurativa Market Size was nearly USD 1.5 billion in the 7MM in 2024. The largest market size was captured by the US. Management involves antibiotics, surgery, and biologics like HUMIRA and COSENTYX. BIMZELX, approved in Europe, is under US FDA review. Biosimilars and emerging therapies, including IL-17, IL-36, JAK, and PDE4 inhibitors, are reshaping the landscape. Pipeline drugs like Sonelokimab, Povorcitinib, and nanobodies show promise. Despite progress, the mild HS segment remains untapped with limited options like orismilast and ruxolitinib cream.
DelveInsight’s “Hidradenitis Suppurativa Market Insights, Epidemiology, and Market Forecast – 2036” report delivers an in-depth understanding of Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Hidradenitis Suppurativa market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Hidradenitis Suppurativa market size from 2022 to 2036, segmented by seven major markets. The Report also covers current Hidradenitis Suppurativa treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Hidradenitis Suppurativa market.
Uncover key insights into the evolving Hidradenitis Suppurativa market—track emerging therapies, forecast trends, and identify untapped opportunities across the 7MM @ Hidradenitis Suppurativa Market Forecast and Drugs Market
Some facts of the Hidradenitis Suppurativa Market Report are:
- According to DelveInsight, Hidradenitis Suppurativa market size is expected to grow at a decent CAGR by 2036.
- In January 2026, MoonLake Immunotherapeutics provided an update following positive feedback from the US Food and Drug Administration (FDA) on the clinical evidence strategy for sonelokimab in hidradenitis suppurativa, following a Type B meeting requested by the company.
- In November 2025, MoonLake Immunotherapeutics announced key upcoming clinical milestones for sonelokimab in hidradenitis suppurativa. The company expects to report 52-week data from the Phase III VELA-1 and VELA-2 trials in adult hidradenitis suppurativa in Q2 2026. In addition, the primary endpoint readout from the Phase III VELA-TEEN trial, evaluating sonelokimab in adolescent patients with hidradenitis suppurativa, is anticipated in Q2 2026.
- In September 2025, Incyte presented new 24-week interim data evaluating the safety and efficacy of povorcitinib from the pivotal Phase III STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa at the European Association of Dermatology and Venereology (EADV) 2025 Congress.
- In July 2025, Novartis announced results of a Randomized, Double-blind, Double-dummy, Placebo-controlled, Multicenter, Phase 3 Study Assessing the Efficacy, Safety, and Tolerability of 2 Doses of Remibrutinib Over a 68-week Treatment Period in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
- In July 2025, Avalo Therapeutics, Inc announced results of a Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa (LOTUS)
- In July 2025, Incyte Corporation announced results of a Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
- In December 2024:- UCB Biopharma SRL- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa. The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS).
- Leading Hidradenitis Suppurativa companies working in the market are Inflarx, Novartis Pharmaceuticals, Incyte Corporation, UCB Biopharma, Janssen Pharmaceuticals, Novartis Pharmaceuticals, Amgen, Chemocentryx, Priovant Therapeutics, Pfizer, Anaptysbio, Abbvie, Acelyrin, Aclaris Therapeutics, Boehringer Ingelheim, Eli Lilly, Moonlake Immunotherapeutics, Aristea Therapeutics, among others.
- Key Hidradenitis Suppurativa Therapies expected to launch in the market are HUMIRA, COSENTYX (secukinumab), BIMZELX (bimekizumab), and others.
- On February 2024, UCB Pharma announced results of a Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
- On March 2024, ACELYRIN Inc announced results of a Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Moderate to Severe Hidradenitis Suppurativa.
- On February 2024, Novartis announced results of a Long Term observAtional, Prospective, Multicenter Study to Collect iN a Real-world populatIon Data on the treatMent Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) (ANIMA).
- On February 2024, Eli Lilly and Company announced results of a Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants With Moderate to Severe Hidradenitis Suppurativa.
- On March 2024, AbbVie announced a Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy.
Hidradenitis Suppurativa Overview
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful, recurrent abscesses, nodules, and tunnels in areas rich in apocrine glands, such as the armpits, groin, and buttocks. The exact cause of Hidradenitis suppurativa is not fully understood but likely involves a combination of genetic predisposition, immune dysregulation, and environmental factors. Hidradenitis suppurativa can significantly impact quality of life due to pain, discomfort, and social stigma associated with the visible lesions.
Diagnosis is based on clinical presentation and may require histopathological examination to confirm. Hidradenitis suppurativa Treatment strategies aim to alleviate symptoms, prevent new lesions, and improve overall well-being. Options include topical and systemic antibiotics, anti-inflammatory medications, immunosuppressants, and biologic therapies, surgical interventions such as drainage and excision, and lifestyle modifications.
Multidisciplinary care involving dermatologists, surgeons, and other specialists is often necessary to manage HS effectively and address the diverse needs of affected individuals.
Learn more about Hidradenitis Suppurativa treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Hidradenitis Suppurativa Treatment Market
Hidradenitis Suppurativa Market
Hidradenitis suppurativa currently has no definitive cure, making early diagnosis and timely treatment essential to slow disease progression, reduce flare severity, and minimize permanent scarring. Treatment strategies are generally tailored according to disease severity and clinical stage. Existing therapeutic approaches include topical and systemic antibiotics, corticosteroids, hormonal therapies, systemic retinoids, zinc supplementation, and immunosuppressive therapies such as biologics. Mild cases are commonly managed with antibacterial cleansers and topical antibiotics, while acute flare-ups may require intralesional corticosteroid injections or minor surgical interventions. Patients with mild-to-moderate disease are often treated with prolonged courses of oral broad-spectrum antibiotics and systemic retinoids. Off-label antibiotics including clindamycin, rifampicin, and tetracycline remain widely utilized due to demonstrated clinical benefits.
The current hidradenitis suppurativa treatment landscape includes approved biologics such as BIMZELX (bimekizumab), COSENTYX (secukinumab), and HUMIRA (adalimumab). HUMIRA maintained a dominant market position for several years despite the expiration of its core US patent in 2016, largely because of AbbVie’s strong secondary patent protections in the United States. However, market dynamics began shifting following the European Commission’s approval of COSENTYX in June 2023 for adults with moderate-to-severe hidradenitis suppurativa who showed inadequate response to conventional systemic therapies. The therapy later secured US FDA approval in October 2023. More recently, in April 2024, the European Commission granted marketing authorization to BIMZELX for treating active moderate-to-severe hidradenitis suppurativa in adults with insufficient response to standard systemic treatment.
According to DelveInsight’s forecasting and analytics team, the emerging pipeline is increasingly focused on advanced dual- and trispecific therapeutic approaches, with investigational candidates such as BIMZELX, Sonelokimab, and Lutikizumab expected to potentially improve long-term patient outcomes and disease management.
The hidradenitis suppurativa pipeline continues to expand with promising therapies including povorcitinib (INCB054707), spesolimab, lutikizumab, eltrekibart, orismilast, ruxolitinib cream, izokibep, and sonelokimab, among others. Despite recent therapeutic advances, the market remains significantly underserved, creating opportunities for multiple blockbuster therapies to coexist similarly to the rheumatoid arthritis treatment landscape.
Additionally, if emerging oral therapies demonstrate efficacy comparable to subcutaneous injectable biologics, patient and physician preference may increasingly shift toward oral treatment options because of convenience and ease of administration.
From a regional perspective, the United States represented the largest hidradenitis suppurativa market within the 7MM, generating nearly USD 1.1 billion in 2023. Among European countries, Germany accounted for the highest market share, while Spain represented the smallest market size. The market share of adalimumab is expected to gradually decline following the introduction of COSENTYX and the anticipated expansion of BIMZELX. By 2036, BIMZELX is projected to generate the highest revenue among all available therapies in the US market.
Hidradenitis Suppurativa Epidemiology
In 2023, the total prevalent cases of hidradenitis suppurativa across the 7MM were estimated at approximately 6.2 million, with the patient population expected to grow steadily through 2036. The United States represented the largest share of diagnosed prevalent cases, reporting nearly 877,600 patients in 2023.
Within the EU4 and the UK, Germany accounted for the highest diagnosed prevalence of hidradenitis suppurativa, whereas Spain reported the lowest patient numbers among the assessed markets.
Gender-based trends showed notable regional variation. In the US, EU4, and the UK, hidradenitis suppurativa was considerably more common among females, who accounted for nearly 75% of cases, compared with around 25% in males. In contrast, Japan demonstrated an opposite trend, with males comprising approximately 70% of diagnosed cases and females representing about 30%.
Age-specific analysis indicated that the disease burden was highest among individuals aged 30–39 years, accounting for nearly 26% of total diagnosed hidradenitis suppurativa cases in the United States. Disease severity segmentation further revealed that Hurley Stage I was the most commonly observed category, with nearly 480,000 prevalent cases reported in the US during 2023.
Explore more about Hidradenitis Suppurativa Epidemiology @ Hidradenitis Suppurativa Prevalence
Hidradenitis Suppurativa Drugs Uptake
Povorcitinib (INCB054707): Incyte Corporation
Povorcitinib, being developed by Incyte Corporation, is an oral selective JAK1 inhibitor designed to reduce inflammatory nodules and abscess formation in patients suffering from moderate-to-severe hidradenitis suppurativa. The therapy is currently under investigation in three separate Phase III STOP-HS clinical studies evaluating its efficacy and safety in moderate-to-severe disease settings. The company anticipates releasing Phase III STOP-HS trial data in 2025 and is targeting a potential commercial launch timeframe between 2026 and 2027 for hidradenitis suppurativa treatment.
Sonelokimab (M1095): MoonLake Immunotherapeutics
Sonelokimab (M1095), developed by MoonLake Immunotherapeutics, is an investigational humanized nanobody therapy with an approximate molecular weight of 40 kDa. The molecule comprises three VHH domains linked through flexible glycine-serine spacers. Nanobody-based therapeutics represent an advanced class of antibody-derived targeted therapies with enhanced specificity and tissue penetration capabilities. Sonelokimab selectively binds with high affinity to IL-17A and IL-17F through two of its domains, thereby blocking IL-17A/A, IL-17A/F, and IL-17F/F dimers involved in inflammatory signaling pathways.
The company has successfully completed a Phase II clinical study assessing sonelokimab in moderate-to-severe hidradenitis suppurativa and is currently advancing the therapy through two global Phase III clinical trials. Topline 24-week data from the Phase II program were presented during the AAD 2024 Annual Meeting. The Phase III development program was initiated following successful end-of-Phase II discussions with the US FDA in February 2024, alongside supportive feedback from the European Medicines Agency regarding the proposed Phase III development strategy.
The ongoing Phase III VELA program is expected to enroll approximately 800 patients across the VELA-1 and VELA-2 studies. Notably, this represents the first Phase III hidradenitis suppurativa program to utilize the more stringent HiSCR75 clinical response threshold as its primary endpoint. According to the company, topline primary endpoint results from the Phase III VELA study at Week 16, along with additional endpoint findings, were anticipated by mid-2025.
Hidradenitis Suppurativa Pipeline Development Activities
The Hidradenitis Suppurativa report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Hidradenitis Suppurativa key players involved in developing targeted therapeutics.
- Povorcitinib (INCB054707): Incyte Corporation
- Izokibep: ACELYRIN
- RINVOQ (upadacitinib): AbbVie
- Lutikizumab (ABT-981): AbbVie
- Sonelokimab (M1095): MoonLake Immunotherapeutics
- Spesolimab: Boehringer Ingelheim
- Brepocitinib (PF-06700841): Priovant Therapeutics
- Eltrekibart (LY3041658): Eli Lilly
- Ruxolitinib 1.5% Cream: Incyte Corporation
- SAR-444656/KT-474: Sanofi/Kymera Therapeutics
- Orismilast: UNION Therapeutics
Request for a sample report to understand more about the Hidradenitis Suppurativa pipeline development activities @ Hidradenitis Suppurativa Medication and FDA Approvals
Hidradenitis Suppurativa Therapeutics Assessment
Major key companies are working proactively in the Hidradenitis Suppurativa Therapeutics market to develop novel therapies which will drive the Hidradenitis Suppurativa treatment markets in the upcoming years are Novartis Pharmaceuticals, UCB Biopharma, Incyte Corporation, AbbVie, Aclaris Therapeutics, Boehringer Ingelheim, UNION Therapeutics, ACELYRIN, Priovant Therapeutics, MoonLake Immunotherapeutics, Eli Lilly, among others
Learn more about the emerging Hidradenitis Suppurativa therapies & key companies @ Hidradenitis Suppurativa Clinical Trials and Recent Developments
Hidradenitis Suppurativa Report Key Insights
1. Hidradenitis Suppurativa Patient Population
2. Hidradenitis Suppurativa Market Size and Trends
3. Key Cross Competition in the Hidradenitis Suppurativa Market
4. Hidradenitis Suppurativa Market Dynamics (Key Drivers and Barriers)
5. Hidradenitis Suppurativa Market Opportunities
6. Hidradenitis Suppurativa Therapeutic Approaches
7. Hidradenitis Suppurativa Pipeline Analysis
8. Hidradenitis Suppurativa Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Hidradenitis Suppurativa Market
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
